The fundraising continues at Minnesota’s Pursuit Vascular, which has reeled in more than $5.1 million through a new equity offering.
Executives disclosed the new cash infusion in a recent regulatory filing, though specific investors are not mentioned.
Pursuit said in February that it had secured $1.6 million in a debt and securities offering to 33 unnamed investors.
Pursuit, which is based in Maple Grove, is attempting to advance its ClearGuard device, an antimicrobial fluid lock designed to kill bacteria and fungi in hemodialysis catheters. It has had FDA approval since late 2013.
President & CEO Doug Killian, most recently president of Sealing Solutions (now owned by St. Jude Medical (NYSE:STJ)), is a veteran industry exec. He held various positions at Boston Scientific (NYSE:BSX) over 13 years, and also held leadership positions at SciMed Life Systems, according to the company’s web site.
Robert Ziebol, Pursuit’s co-founder and vice president of R&D, launched Pursuit in 2008.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!